What it is

Melanotan II (MT-II) is a synthetic melanocortin peptide agonist developed from α-melanocyte-stimulating hormone (α-MSH) research. It activates melanocortin receptors involved in pigmentation and also receptors involved in sexual function, appetite, and autonomic effects.

Melanotan II is not FDA-approved. Products sold online are unregulated and commonly used for cosmetic tanning despite the lack of approved indication.

Why people use it

Most non-medical use is for tanning and cosmetic pigmentation changes. Some interest also comes from reports of libido effects, which align with melanocortin receptor biology, but this is not an approved or well-controlled therapeutic use for MT-II.

History and origin

MT-II emerged from medicinal chemistry efforts to create more stable melanocortin analogs with potent receptor activity. Its development history is closely tied to broader melanocortin drug discovery, including compounds that eventually led to approved therapies in related mechanistic space (for example, bremelanotide is also a melanocortin agonist, but it is a distinct drug with FDA approval for a specific indication).

How it works

MT-II is a melanocortin receptor agonist. Activation of MC1R in melanocytes increases eumelanin production, contributing to pigmentation. Activity at other melanocortin receptors (such as MC3R/MC4R) is associated with effects on appetite and autonomic functions, and MC4R-related pathways are implicated in sexual function effects seen with melanocortin agonists.

Because MT-II is not receptor-selective for a single endpoint, side effects can plausibly arise from on-target receptor activation outside pigmentation.

Evidence landscape

There is a substantial scientific literature on melanocortin receptors and melanocortin agonists, but MT-II’s real-world use has largely occurred outside regulated clinical programs. Reports include case literature describing serious adverse events temporally associated with MT-II use, as well as broader discussion of population use and risks.

Safety reality

Safety concerns include nausea, flushing, changes in blood pressure, and unpredictable systemic effects from melanocortin receptor activation. There are also concerns about changes in nevi and pigmentation patterns, and about the risk of contaminated or incorrectly synthesized products. Severe adverse events have been reported in case literature.

References

Melanotan-associated melanoma (2011). https://pubmed.ncbi.nlm.nih.gov/21564053/

Melanotan-induced priapism: a hard-earned tan (2019). https://pubmed.ncbi.nlm.nih.gov/30796078/

Melanotan II overdose associated with priapism (2013). https://pubmed.ncbi.nlm.nih.gov/23537392/

Melanotan II (MT-II) + NB-UVB for Vitiligo Repigmentation (ClinicalTrials.gov). https://clinicaltrials.gov/study/NCT07437560